Abstract
Chinese hamster ovary (CHO) cells are promising host engineering cells for industry manufacturing of therapeutic antibodies. However, cell death due to apoptosis remains a huge challenge to augment antibody production, and developing CHO cells with enhanced anti-apoptosis and proliferation ability is fundamental for cell line development and high-yielding bioprocesses. Deubiquitinase cylindromatosis (CYLD) has been proved to be a tumor suppressor by negatively regulating NF-κB and Wnt/β-catenin signaling pathways. Its mutation or deletion is a common chromosome variation in several types of cancers. Here, we engineered CHO CYLD−/− cells by CRISPR-Cas9 editing technology. These cells displayed stronger cell proliferation and anti-apoptosis ability compared to parental cells. Three antibody expression plasmid kits were transiently transfected into these cells. Our data showed that inactivation of CYLD increased the highest titers of rituximab, Herceptin, and one bispecific antibody by 105, 63, and 228%, respectively. Reversely, overexpression of CYLD could promote cell apoptosis, whereas inhibiting cell proliferation and antibody production. Furthermore, inhibition of CYLD in CHO cells stably expressing an IgG antibody (CHO-IgG) achieved about 50% increase in product titer compared to parental cells. Meanwhile, inhibition of CYLD did not affect the quality of antibody. Thus, our data demonstrated that inactivation of CYLD could promote CHO cell proliferation, anti-apoptosis ability, and subsequent antibody production, suggesting that CYLD is a potential functional target for CHO cell engineering.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aggarwal RS (2014) What’s fueling the biotech engine—2012 to 2013. Nat Biotechnol 32:32–39. https://doi.org/10.1038/nbt.2794
Astley K, Naciri M, Racher A, Al-Rubeai M (2007) The role of p21cip1 in adaptation of CHO cells to suspension and protein-free culture. J Biotechnol 130:282–290. https://doi.org/10.1016/j.jbiotec.2007.04.012
Bi JX, Shuttleworth J, Al-Rubeai M (2004) Uncoupling of cell growth and proliferation results in enhancement of productivity in p21CIP1-arrested CHO cells. Biotechnol Bioeng 85:741–749. https://doi.org/10.1002/bit.20025
Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J, Rasmussen S (2000) Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 25:160–165. https://doi.org/10.1038/76006
Brown AJ, Sweeney B, Mainwaring DO, James DC (2014) Synthetic promoters for CHO cell engineering. Biotechnol Bioeng 111:1638–1647. https://doi.org/10.1002/bit.25227
Brown AJ, Sweeney B, Mainwaring DO, James DC (2015) NF-kappaB, CRE and YY1 elements are key functional regulators of CMV promoter-driven transient gene expression in CHO cells. Biotechnol J 10:1019–1028. https://doi.org/10.1002/biot.201400744
Brummelkamp TR, Nijman SM, Dirac AM, Bernards R (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424:797–801. https://doi.org/10.1038/nature01811
Carlage T, Hincapie M, Zang L, Lyubarskaya Y, Madden H, Mhatre R, Hancock WS (2009) Proteomic profiling of a high-producing Chinese hamster ovary cell culture. Anal Chem 81:7357–7362. https://doi.org/10.1021/ac900792z
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823. https://doi.org/10.1126/science.1231143
Courtes FC, Vardy L, Wong NS, Bardor M, Yap MG, Lee DY (2014) Understanding translational control mechanisms of the mTOR pathway in CHO cells by polysome profiling. New Biotechnol 31:514–523. https://doi.org/10.1016/j.nbt.2013.10.003
Deng LL, Shao YX, Lv HF, Deng HB, Lv FZ (2012) Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-kappaB survival signaling in lung cancer cells. Neoplasma 59:18–29. https://doi.org/10.4149/neo_2012_003
Doolan P, Meleady P, Barron N, Henry M, Gallagher R, Gammell P, Melville M, Sinacore M, McCarthy K, Leonard M, Charlebois T, Clynes M (2010) Microarray and proteomics expression profiling identifies several candidates, including the valosin-containing protein (VCP), involved in regulating high cellular growth rate in production CHO cell lines. Biotechnol Bioeng 106:42–56. https://doi.org/10.1002/bit.22670
Espinosa L, Cathelin S, D’Altri T, Trimarchi T, Statnikov A, Guiu J, Rodilla V, Ingles-Esteve J, Nomdedeu J, Bellosillo B, Besses C, Abdel-Wahab O, Kucine N, Sun SC, Song G, Mullighan CC, Levine RL, Rajewsky K, Aifantis I, Bigas A (2010) The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 18:268–281. https://doi.org/10.1016/j.ccr.2010.08.006
Fan Y, Jimenez Del Val I, Muller C, Wagtberg Sen J, Rasmussen SK, Kontoravdi C, Weilguny D, Andersen MR (2015) Amino acid and glucose metabolism in fed-batch CHO cell culture affects antibody production and glycosylation. Biotechnol Bioeng 112:521–535. https://doi.org/10.1002/bit.25450
Fernández-Majada V, Welz PS, Ermolaeva MA, Schell M, Adam A, Dietlein F, Komander D, Büttner R, Thomas RK, Schumacher B, Pasparakis M (2016) The tumour suppressor CYLD regulates the p53 DNA damage response. Nat Commun 7:12508. https://doi.org/10.1038/ncomms12508
Fischer S, Mathias S, Schaz S, Emmerling VV, Buck T, Kleemann M, Hackl M, Grillari J, Aschrafi A, Handrick R, Otte K (2015) Enhanced protein production by microRNA-30 family in CHO cells is mediated by the modulation of the ubiquitin pathway. J Biotechnol 212:32–43. https://doi.org/10.1016/j.jbiotec.2015.08.002
Friedman CS, O'Donnell MA, Legarda-Addison D, Ng A, Cardenas WB, Yount JS, Moran TM, Basler CF, Komuro A, Horvath CM, Xavier R, Ting AT (2008) The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep 9:930–936. https://doi.org/10.1038/embor.2008.136
Gulis G, Simi KC, de Toledo RR, Maranhao AQ, Brigido MM (2014) Optimization of heterologous protein production in Chinese hamster ovary cells under overexpression of spliced form of human X-box binding protein. BMC Biotechnol 14:26. https://doi.org/10.1186/1472-6750-14-26
Hacker DL, De Jesus M, Wurm FM (2009) 25 years of recombinant proteins from reactor-grown cells—where do we go from here? Biotechnol Adv 27:1023–1027. https://doi.org/10.1016/j.biotechadv.2009.05.008
Hammond S, Swanberg JC, Polson SW, Lee KH (2012) Profiling conserved microRNA expression in recombinant CHO cell lines using Illumina sequencing. Biotechnol Bioeng 109:1371–1375. https://doi.org/10.1002/bit.24415
Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M, Murakami K, Yamashita S, Yamamoto Y, Li JD, Iwase H, Ando Y (2014) Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res Treat 143:447–457. https://doi.org/10.1007/s10549-013-2824-3
Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, Bosserhoff AK (2007) Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28:21–27. https://doi.org/10.1093/carcin/bgl081
Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479. https://doi.org/10.1146/annurev.biochem.67.1.425
Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, Yuan J (2008) Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 135:1311–1323. https://doi.org/10.1016/j.cell.2008.10.044
Huang A, Madan RK, Levitt J (2016) Future therapies for pemphigus vulgaris: rituximab and beyond. J Am Acad Dermatol 74:746–753. https://doi.org/10.1016/j.jaad.2015.11.008
Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K (2010) STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39:493–506. https://doi.org/10.1016/j.molcel.2010.07.023
Jaluria P, Betenbaugh M, Konstantopoulos K, Shiloach J (2007) Enhancement of cell proliferation in various mammalian cell lines by gene insertion of a cyclin-dependent kinase homolog. BMC Biotechnol 7:71. https://doi.org/10.1186/1472-6750-7-71
Johari YB, Estes SD, Alves CS, Sinacore MS, James DC (2015) Integrated cell and process engineering for improved transient production of a “difficult-to-express” fusion protein by CHO cells. Biotechnol Bioeng 112:2527–2542. https://doi.org/10.1002/bit.25687
Karpel-Massler G, Banu MA, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD (2016) Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo. Oncotarget 7:12791–12805. https://doi.org/10.18632/oncotarget.7302
Kelly PS, Gallagher C, Clynes M, Barron N (2015) Conserved microRNA function as a basis for Chinese hamster ovary cell engineering. Biotechnol Lett 37:787–798. https://doi.org/10.1007/s10529-014-1751-7
Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424:801–805. https://doi.org/10.1038/nature01802
Kuystermans D, Al-Rubeai M (2009) cMyc increases cell number through uncoupling of cell division from cell size in CHO cells. BMC Biotechnol 9:76. https://doi.org/10.1186/1472-6750-9-76
Lee JS, Ha TK, Park JH, Lee GM (2013) Anti-cell death engineering of CHO cells: co-overexpression of Bcl-2 for apoptosis inhibition, Beclin-1 for autophagy induction. Biotechnol Bioeng 110:2195–2207. https://doi.org/10.1002/bit.24879
Lim SF, Chuan KH, Liu S, Loh SO, Chung BY, Ong CC, Song Z (2006) RNAi suppression of Bax and Bak enhances viability in fed-batch cultures of CHO cells. Metab Eng 8:509–522. https://doi.org/10.1016/j.ymben.2006.05.005
Lim JH, Stirling B, Derry J, Koga T, Jono H, Woo CH, Xu H, Bourne P, Ha UH, Ishinaga H, Xu H, Andalibi A, Feng XH, Zhu H, Huang Y, Zhang W, Weng X, Yan C, Yin Z, Briles DE, Davis RJ, Flavell RA, Li JD (2007) Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 27:349–360. https://doi.org/10.1016/j.immuni.2007.07.011
Loh WP, Loo B, Zhou L, Zhang P, Lee DY, Yang Y, Lam KP (2014) Overexpression of microRNAs enhances recombinant protein production in Chinese hamster ovary cells. Biotechnol J 9:1140–1151. https://doi.org/10.1002/biot.201400050
Majors BS, Betenbaugh MJ, Chiang GG (2007) Links between metabolism and apoptosis in mammalian cells: applications for anti-apoptosis engineering. Metab Eng 9:317–326. https://doi.org/10.1016/j.ymben.2007.05.003
Misaghi S, Qu Y, Snowden A, Chang J, Snedecor B (2013) Resilient immortals, characterizing and utilizing Bax/Bak deficient Chinese hamster ovary (CHO) cells for high titer antibody production. Biotechnol Prog 29:727–737. https://doi.org/10.1002/btpr.1722
Onitsuka M, Kinoshita Y, Nishizawa A, Tsutsui T, Omasa T (2017) Enhanced IgG1 production by overexpression of nuclear factor kappa B inhibitor zeta (NFKBIZ) in Chinese hamster ovary cells. Cytotechnology 70:675–685. https://doi.org/10.1007/s10616-017-0170-8
Puck TT, Cieciura SJ, Robinson A (1958) Genetics of somatic mammalian cells. III. Long-term cultivation of euploid cells from human and animal subjects. J Exp Med 108:945–956. https://doi.org/10.1084/jem.108.6.945
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8:2281–2308. https://doi.org/10.1038/nprot.2013.143
Reiley W, Zhang M, Wu X, Granger E, Sun SC (2005) Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol Cell Biol 25:3886–3895. https://doi.org/10.1128/MCB.25.10.3886-3895.2005
Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, Schwaiger M, Stubenrauch KG, Sustmann C, Thomas M, Scheuer W, Klein C (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 108:11187–11192. https://doi.org/10.1073/pnas.1019002108
Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348:56–61. https://doi.org/10.1126/science.aaa8172
Strotbek M, Florin L, Koenitzer J, Tolstrup A, Kaufmann H, Hausser A, Olayioye MA (2013) Stable microRNA expression enhances therapeutic antibody productivity of Chinese hamster ovary cells. Metab Eng 20:157–166. https://doi.org/10.1016/j.ymben.2013.10.005
Sung YH, Lee JS, Park SH, Koo J, Lee GM (2007) Influence of co-down-regulation of caspase-3 and caspase-7 by siRNAs on sodium butyrate-induced apoptotic cell death of Chinese hamster ovary cells producing thrombopoietin. Metab Eng 9:452–464. https://doi.org/10.1016/j.ymben.2007.08.001
Tauriello DV, Haegebarth A, Kuper I, Edelmann MJ, Henraat M, Canninga-van Dijk MR, Kessler BM, Clevers H, Maurice MM (2010) Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell 37:607–619. https://doi.org/10.1016/j.molcel.2010.01.035
Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424:793–796. https://doi.org/10.1038/nature01803
van Andel H, Kocemba KA, de Haan-Kramer A, Mellink CH, Piwowar M, Broijl A, van Duin M, Sonneveld P, Maurice MM, Kersten MJ, Spaargaren M, Pals ST (2017) Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease. Oncogene 36:2105–2115. https://doi.org/10.1038/onc.2016.368
von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L (2016) Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 34:4381–4389. https://doi.org/10.1200/JCO.2016.67.3301
Wickström SA, Masoumi KC, Khochbin S, Fassler R, Massoumi R (2010) CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J 29:131–144. https://doi.org/10.1038/emboj.2009.317
Xu X, Nagarajan H, Lewis NE, Pan S, Cai Z, Liu X, Chen W, Xie M, Wang W, Hammond S, Andersen MR, Neff N, Passarelli B, Koh W, Fan HC, Wang J, Gui Y, Lee KH, Betenbaugh MJ, Quake SR, Famili I, Palsson BO, Wang J (2011) The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat Biotechnol 29:735–741. https://doi.org/10.1038/nbt.1932
Xu C, He X, Zheng Z, Zhang Z, Wei C, Guan K, Hou L, Zhang B, Zhu L, Cao Y, Zhang Y, Cao Y, Ma S, Wang P, Zhang P, Xu Q, Ling Y, Yang X, Zhong H (2014) Downregulation of microRNA miR-526a by enterovirus inhibits RIG-I-dependent innate immune response. J Virol 88:11356–11368. https://doi.org/10.1128/JVI.01400-14
Xu C, Yang L, Yuan Y, Du F, Wang S, Wang X, Zhu L, Zhang B, Weaver D (2016) Up-regulation of CYLD enhances Listeria monocytogenes induced apoptosis in THP-1 cells. Microb Pathog 90:50–54. https://doi.org/10.1016/j.micpath.2015.10.007
Yang X, Wang C, Xu C, Yan Z, Wei C, Guan K, Ma S, Cao Y, Liu L, Zou D, He X, Zhang B, Ma Q, Zheng Z (2015) miR-526a regulates apoptotic cell growth in human carcinoma cells. Mol Cell Biochem 407:69–76. https://doi.org/10.1007/s11010-015-2455-6
Ye H, Liu X, Lv M, Wu Y, Kuang S, Gong J, Yuan P, Zhong Z, Li Q, Jia H, Sun J, Chen Z, Guo AY (2012) MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res 40:5201–5214. https://doi.org/10.1093/nar/gks175
Zeitlin L, Whaley KJ, Olinger GG, Jacobs M, Gopal R, Qiu X, Kobinger GP (2016) Antibody therapeutics for Ebola virus disease. Curr Opin Virol 17:45–49. https://doi.org/10.1016/j.coviro.2016.01.006
Funding
This work was supported by the National Natural Science Foundation of China (Grant 31600749) and the Initial Foundation of Doctoral Scientific Research in Anhui University (Y01001487).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
This article does not contain any studies with human participants or animals performed by any of the authors.
Conflict of interest
The authors declare that they do not have conflicts of interest.
Electronic supplementary material
ESM 1
(PDF 423 kb)
Rights and permissions
About this article
Cite this article
Lu, Y., Zhou, Q., Han, Q. et al. Inactivation of deubiquitinase CYLD enhances therapeutic antibody production in Chinese hamster ovary cells. Appl Microbiol Biotechnol 102, 6081–6093 (2018). https://doi.org/10.1007/s00253-018-9070-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00253-018-9070-x